Clinical Data and Practical Considerations for BCMA-Directed Antibody-Drug Conjugates in Relapsed/Refractory Multiple Myeloma

Dr. Paul Richardson discusses clinical data and practical considerations for belantamab mafodotin as a BCMA-directed antibody-drug conjugate in relapsed/refractory multiple myeloma, highlighting findings from the DREAMM-7 study. He emphasizes the progression-free survival and overall survival outcomes observed with the combination regimen and discusses how dosing and ocular monitoring can help make ocular toxicity a manageable consideration. Dr. Richardson contrasts the outpatient administration and off-the-shelf availability of belantamab mafodotin with the logistical demands associated with other cellular therapies. He also describes his experience using the therapy in clinical practice and discusses its potential relevance for patients who may not be candidates for CAR T-cell therapy or bispecific antibodies. The conversation then turns to treatment sequencing, with Dr. Richardson emphasizing the potential flexibility of incorporating belantamab mafodotin at different points in a patient's treatment course. Dr. Lee and Dr. Richardson further discuss the expanding role of BCMA-directed therapies and the availability of multiple treatment approaches for patients with relapsed/refractory multiple myeloma.